Recent clinical trials
If you are interested in participating in a clinical trial at Aurora Health Care, learn more on our Web site.
- Randomized clinical trial testing of a new drug for non-constipating irritable bowel syndrome. Nimish Vakil, M.D., principal investigator.
- Randomized clinical trail testing of a new drug for gastroesophageal research disease (GERD). Nimish Vakil, M.D., Peter Johnson, M.D., principal investigators.
- Study of a device to close a patient foramen ovale (hole in the heart). Randomized to medical management for patients who have had a stroke or a mini-stroke. Tanvir Bajwa, M.D., principal investigator.
- Randomized clinical trail testing of a new drug for pulmonary hypertension. Dianne Zwicke, M.D., principal investigator.
- Study to evaluate a new test that measures YKL-40 to see if the amount of YKL-40 in the blood can help monitor ovarian cancer. Peter Johnson, M.D., principal investigator.
- Study to compare the effectiveness, safety, and the impact on health-related quality of life of cisplatin and paclitaxel, cisplantin and paclitaxel plus bevacizumab, paclitaxel and topotecan, as well as paclitaxel and topotecan plus bevacizumab for patients with cancer of the cervix that is not curable by surgery or radiation therapy. Peter Johnson, M.D., principal investigator
- Study to compare the effects of radiation therapy to the pelvis with vaginal radiation therapy combined with three cycles of the chemotherapy drugs paclitaxel and carboplatin to find out which works better in reducing the chance that of recurrence of cancer for patients with high-risk early stage endometrial cancer that appears to be confined to the uterus. Peter Johnson, M.D., principal investigator.
- A minimal risk "observational" study that will enroll 720 lung cancer patients, including 120 female never-smokers (less than 100 cigarettes lifetime), 120 male never-smokers, 240 female smokers, and 240 male smokers. Mitchell Pincus, M.D., principal investigator.
- Testing the use of artificial iris lens implants to treat congenital anomalies and eyes damaged by surgical or severe trauma. The Model 311 Artificial Iris Lens was designed to reduce, minimize or eliminate visual disturbances caused by the lack of adequate iris tissue. Kevin Weinker, M.D., principal investigator.